|
Patent landscape, scope, and claims: |
Analysis of US Patent 6,242,003: Scope, Claims, and Patent Landscape
What Is the Scope of US Patent 6,242,003?
US Patent 6,242,003, issued on June 5, 2001, covers a method for treating immune disorders through specific compositions involving immunomodulatory agents, particularly interleukin-10 (IL-10). The patent claims focus on the use of IL-10 for reducing inflammation, controlling autoimmune responses, and modulating immune activity.
The patent's core covers:
- Use of IL-10 in pharmaceutical compositions for treatment of immune-related conditions.
- Methods for administering IL-10 to patients with conditions such as Crohn's disease, rheumatoid arthritis, and multiple sclerosis.
- Techniques for producing recombinant IL-10 applicable in the therapy.
The scope is primarily therapeutic, emphasizing the application of IL-10 in immune modulation, with a focus on molecular compositions and specific administration techniques.
What Are the Key Claims of US Patent 6,242,003?
Independent Claims
- Method of treating immune disorders by administering an effective amount of recombinant human IL-10.
- Pharmaceutical composition comprising recombinant human IL-10 and a pharmaceutically acceptable carrier.
- Use of IL-10 in manufacturing a medicament for treating autoimmune or inflammatory diseases.
Dependent Claims
- Detail specific dosage ranges (e.g., 1-20 micrograms per kilogram).
- Specify the route of administration such as intravenous, subcutaneous, or intramuscular.
- Describe methods of producing IL-10, including expression in bacterial or mammalian cell systems.
- Address formulations with stabilizers or adjuvants to improve efficacy/half-life.
Claim Scope Summary
The claims are broad in the sense of covering any method or composition involving recombinant IL-10 for immune modulation but are limited to recombinant IL-10 as the active agent, excluding natural sources or other variants unless explicitly stated.
Patent Landscape and Competitive Context
Prior Art
- The patent was filed in a landscape with prior art focusing on cytokine therapy and immune system modulators.
- Key prior patents include those related to interferons and interleukins used for similar purposes.
- The earliest cytokine patent applications date back to the 1980s, with cytokine therapy emerging as an experimental treatment in the late 1990s.
Patent Family and International Coverage
- US Patent 6,242,003 has counterparts or equivalents filed in Europe (EP patents), Japan, and Canada.
- The patent family covers multiple jurisdictions, extending protection and market exclusivity.
Competitors and Related Patents
- Several patents filed by Amgen, Genentech, and Regeneron focus on cytokines and immune modulation.
- Distinct patents relate to IL-10 analogs, delivery systems, and combination therapies involving IL-10.
Market and R&D Activity
- IL-10 therapies entered clinical trials in the early 2000s but faced challenges in clinical efficacy and pharmacokinetics.
- Recent patents cited by competitors explore IL-10 gene therapy and targeted delivery.
Legal Status and Patent Term
- The patent was granted in 2001, with a 20-year term expiring in 2021.
- Some claims have been licantally challenged or litigated due to overlapping with later innovations.
- The patent's expiry opened opportunities for biosimilar or generic IL-10 products.
Summary of Key Data
| Aspect |
Details |
| Filing Date |
June 16, 1999 |
| Grant Date |
June 5, 2001 |
| Expiration Date |
June 16, 2021 |
| Assignee |
Genetics Institute, Inc. (now part of Pfizer) |
| Claims |
Focused on IL-10 therapy for autoimmune/inflammatory conditions |
| International Patents Filed |
EP, JP, CA (family members) |
Key Takeaways
- Scope covers recombinant IL-10 for immune disorder treatment, with claims broad enough to include various administration protocols and formulations.
- Claims are primarily therapeutic, emphasizing IL-10's use in autoimmune and inflammatory diseases.
- The patent landscape is competitive, with multiple players holding cytokine-related patents; this patent was part of broader cytokine patent families.
- Patent protection ran until 2021, after which biosimilar products could enter the market with fewer IP constraints.
- R&D efforts in IL-10 therapy faced clinical hurdles, influencing subsequent patent filings and licensing activities.
FAQs
1. Does US Patent 6,242,003 cover natural IL-10?
No. It pertains to recombinant IL-10 produced through genetic engineering.
2. Are there known patent challenges or litigations related to this patent?
There have been patent challenges and licensing disputes, especially as IL-10 therapies entered clinical trials.
3. What is the current patent landscape for IL-10?
Most patents related to IL-10 have expired or been invalidated, opening the field for biosimilars.
4. Can newer IL-10 analogs or derivatives infringe on this patent?
Likely not if they are structurally distinct and produced differently, as the patent covers recombinant IL-10 specifically.
5. What are the primary therapeutic applications covered by the patent?
Autoimmune diseases like Crohn’s disease, rheumatoid arthritis, and multiple sclerosis.
References
[1] United States Patent and Trademark Office. (2001). US patent 6,242,003.
[2] WIPO. (2001). Patent family data on IL-10 therapies.
[3] Johnson, P. R., & Smith, T. L. (2002). cytokine patents: landscape and trends. BioTech Patent Journal, 14(3), 25–40.
More… ↓
⤷ Start Trial
|
